Health TrialsbyHealthPanel

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

ConditionsAdvanced Thyroid Gland Medullary CarcinomaStage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center

About this trial

This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aims 1 and 2: A diagnosis of MTC

Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment

Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team

Aim 3: A current registrant in the MTCR

Disqualifiers

None

Trial population

Patients diagnosed with MTC including advanced phase MTC determined by clinical team

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Blood Pressure Measurement

    Other intervention

    Undergo blood pressure measurement

  • Questionnaire Administration

    Other intervention

    Complete questionnaires

Treatment groups

2,030 Participants
are divided into 1 treatment group
Group A: Observational (questionnaire, blood pressure)2 interventions

Trial outcomes

Primary outcomes

1

Natural history of medullary thyroid cancer (MTC)

Will describe the natural history of MTC using comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in existing multi-institutional patient registry.

Time frame
Up to 4 years
2

Patients' experience with the different phases of MTC

Will characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs).

Time frame
Up to 4 years
3

Association of selected biometric and patient-reported outcomes

Will evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial.

Time frame
Up to 4 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov
Apply now